Vertex Reports Second-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Vertex Pharma (VRTX) Tops Q2 EPS by 19c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus
July 31, 2019 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $1.26, $0.19 better than the analyst estimate of $1.07. Revenue for the quarter came in at $941.29 million versus the consensus estimate of $885.58 million.
"We have made tremendous progress across our business in 2019 thus far. In... More
